Jump Financial, LLC Oric Pharmaceuticals, Inc. Transaction History

Jump Financial, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$7.52 - $11.9 $148,316 - $234,703	-19,723 Closed	0 $0
Q2 2024 Aug 14, 2024	BUY	$6.63 - $12.93 $130,763 - $255,018	19,723 New	19,723 $139,000
Q3 2023 Oct 21, 2024	BUY	$6.05 - $9.28 $99,516 - $152,646	16,449 Added 104.77%	32,149 $194,000
Q3 2023 Nov 07, 2023	BUY	$6.05 - $9.28 $99,516 - $152,646	16,449 Added 104.77%	32,149 $194,000
Q2 2023 Oct 21, 2024	SELL	$4.95 - $8.4 $42,812 - $72,651	-8,649 Reduced 35.52%	15,700 $121,000
Q2 2023 Aug 07, 2023	SELL	$4.95 - $8.4 $42,812 - $72,651	-8,649 Reduced 35.52%	15,700 $121,000
Q1 2023 Oct 21, 2024	BUY	$4.26 - $6.75 $19,706 - $31,225	4,626 Added 23.45%	24,349 $138,000
Q1 2023 May 03, 2023	BUY	$4.26 - $6.75 $103,726 - $164,355	24,349 New	24,349 $138,000
Q2 2022 Aug 09, 2022	SELL	$2.7 - $7.07 $108,000 - $282,800	-40,000 Closed	0 $0
Q1 2022 May 12, 2022	BUY	$4.54 - $16.1 $181,600 - $644,000	40,000 New	40,000 $213,000

124

66.6M

7.8K

700

Ticker ORIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,576,700
Market Cap $336M
Description
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment r...

Get notified when there are updates to the investment portfolio of Jump Financial, LLC, based on Form 13F filings with the SEC.

Stay updated on Jump Financial, LLC with notifications on news.